Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00279539Phase 1Withdrawn

Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure

Role: lead

NCT00311805Phase 1Unknown

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

Role: lead

NCT00620048Phase 1Terminated

Stem Cell Study for Subjects With Congestive Heart Failure

Role: lead

NCT00616980Phase 1Completed

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

Role: lead

NCT00056290Phase 1Completed

VEGF Gene Transfer for Diabetic Neuropathy

Role: lead

NCT00304837Phase 1Completed

VEGF Gene Transfer for Critical Limb Ischemia

Role: lead

NCT00346177Phase 2Withdrawn

Stem Cell Study for Patients With Heart Failure

Role: lead

NCT00081913Phase 1Completed

Stem Cell Study for Patients With Heart Disease

Role: lead

All 8 trials loaded